Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9ULJ6

UPID:
ZMIZ1_HUMAN

ALTERNATIVE NAMES:
PIAS-like protein Zimp10; Retinoic acid-induced protein 17

ALTERNATIVE UPACC:
Q9ULJ6; Q5JSH9; Q7Z7E6

BACKGROUND:
Zinc finger MIZ domain-containing protein 1, known alternatively as PIAS-like protein Zimp10 or Retinoic acid-induced protein 17, is integral to transcriptional regulation. It enhances AR ligand-dependent activity through sumoylation and boosts the SMAD3/SMAD4 complex's activity within the TGF-beta pathway. Furthermore, it activates certain NOTCH1 target genes like MYC and is crucial for thymocyte, T cell development, and cerebral cortex neuron positioning.

THERAPEUTIC SIGNIFICANCE:
Linked to a neurodevelopmental disorder with diverse manifestations such as developmental delay and facial dysmorphism, Zinc finger MIZ domain-containing protein 1's functional understanding could pave the way for innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.